Focused On-demand Library for Phenylalanine-4-hydroxylase

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

PARTNER
Receptor.AI
 
UPACC
P00439

UPID:
PH4H_HUMAN

ALTERNATIVE NAMES:
Phe-4-monooxygenase

ALTERNATIVE UPACC:
P00439; Q16717; Q8TC14

BACKGROUND:
The enzyme Phenylalanine-4-hydroxylase, with its alternative name Phe-4-monooxygenase, is essential for the hydroxylation of L-phenylalanine to L-tyrosine, a key step in phenylalanine degradation.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Phenylalanine-4-hydroxylase could open doors to potential therapeutic strategies for treating metabolic disorders like Phenylketonuria and its milder forms, highlighting the enzyme's significance in medical research and drug development.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 8780 of 8789